Diligence memo · auto-generated · as of July 2, 2026
MetaStat, Inc.
MetaStat, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
MetaStat, Inc. operates in Biotechnology, based in Boston.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
MetaStat, Inc. has raised $39M in disclosed capital across 16 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2014-07-01.
Most recent recorded round closed around 2018-03-30.
Valuation (modeled)modeled
Provath models MetaStat, Inc. at approximately $122M (range $3.7M–$664M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.58× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 8.3 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 78% of Biotechnology peers (4293 compared).
Modeled value ranks above 63% of those peers.
Closest niche peers: Bio-Dent, LTD. LLC, Anthera Pharmaceuticals Inc, Cynvec LLC, Biothera Holding Corp., Limelight Bio, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.